The publisher / Editorial only
About GHK-Cu Safe
An independent reading of the copper-peptide literature — what it is, what it is not, and why the name says "safe."
What this site is
GHK-Cu Safe is an independent editorial project that publishes summaries of the peer-reviewed research literature on GHK-Cu, the copper-binding tripeptide also labeled Copper Tripeptide-1. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The approach is deliberately calm and even-handed. GHK-Cu has a genuinely strong preclinical record — picomolar collagen stimulation [1], a 31%-of-the-genome expression signature [2], a controlled hair-count trial [4] — and it has real limits: no validated human pharmacokinetics, small human sample sizes, and a literature weighted toward one research group [3][2]. We present both, lead with what was measured, and attribute every number to its study.
Why the name says "safe"
The word "safe" in this site's name is editorial framing, not a safety claim about the compound. It describes the way we read — carefully, with the gaps left visible, weighing the evidence before repeating it — not a verdict that GHK-Cu is safe to use by any route. Topical Copper Tripeptide-1 has a long cosmetic record; systemic GHK-Cu is unapproved and lacks validated human safety data [3].
We take that distinction seriously enough to repeat it: nothing here is a recommendation to use GHK-Cu, and nothing here is a dosing protocol. The closest thing to dosing on this site is a description of what concentrations and routes appeared in published studies, framed strictly as research context [3]. A reader weighing the literature should leave knowing both the findings and their boundaries.
How we work
Every page leads with findings and cites them inline, resolving to a full reference list with DOIs and PubMed identifiers. When a figure is contested — the 4,000-gene claim, for instance — we note the correction the literature itself supplies [2]. When a study tested an analog or a combination rather than pure GHK-Cu, we say so [4][8].
We describe research; we do not prescribe. We use generic compound names only. And we keep the safety gaps in the same paragraph as the benefits, because that is the only honest way to summarize a molecule whose preclinical promise has outrun its controlled human evidence.